ARDELYX, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ARDELYX, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $85.0K | Mar 6, 2019 |
| FY2018 | Sep 30, 2018 | $172.0K | Mar 6, 2019 |
| FY2018 | Jun 30, 2018 | $30.0K | Mar 6, 2019 |
| FY2018 | Mar 31, 2018 | $2.32M | Mar 6, 2019 |
| FY2018 | Dec 31, 2017 | $42.00M | Mar 6, 2019 |
| FY2017 | Dec 31, 2015 | $24.03M | Mar 14, 2018 |
| FY2016 | Jun 30, 2015 | $18.14M | Feb 17, 2017 |
| FY2016 | Mar 31, 2015 | $5.88M | Feb 17, 2017 |
| FY2015 | Dec 31, 2014 | $6.34M | Mar 4, 2016 |
| FY2015 | Sep 30, 2014 | $7.60M | Mar 4, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $407.32M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $333.62M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $124.46M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $52.16M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $10.10M | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | $1.81M | Mar 8, 2021 |
| FY2020 | Sep 30, 2020 | $2.71M | Mar 8, 2021 |
| FY2020 | Jun 30, 2020 | $1.84M | Mar 8, 2021 |
| FY2020 | Mar 31, 2020 | $1.21M | Mar 8, 2021 |
| FY2020 | Dec 31, 2019 | $2.25M | Mar 8, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $2.25M | Mar 6, 2020 |
| FY2019 | Sep 30, 2019 | $2.41M | Mar 6, 2020 |
| FY2019 | Jun 30, 2019 | $18.0K | Mar 6, 2020 |
| FY2019 | Dec 31, 2018 | $85.0K | Mar 6, 2020 |
| FY2019 | Sep 30, 2018 | $170.0K | Mar 6, 2020 |
| FY2019 | Jun 30, 2018 | $30.0K | Mar 6, 2020 |
| FY2019 | Mar 31, 2018 | $1.86M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | $33.60M | Mar 6, 2019 |
| FY2017 | Dec 31, 2015 | $24.03M | Mar 14, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($61.60M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($39.14M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($66.07M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($67.21M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | ($158.17M) | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | ($28.88M) | Mar 8, 2021 |
| FY2020 | Sep 30, 2020 | ($18.11M) | Mar 8, 2021 |
| FY2020 | Jun 30, 2020 | ($24.96M) | Mar 8, 2021 |
| FY2020 | Mar 31, 2020 | ($22.37M) | Mar 8, 2021 |
| FY2020 | Dec 31, 2019 | ($19.79M) | Mar 8, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($40.98M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($27.95M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($63.28M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($63.76M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | ($154.35M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | ($90.78M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | ($91.26M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($90.95M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | ($65.12M) | Mar 6, 2020 |
| FY2018 | Dec 31, 2016 | ($112.90M) | Mar 6, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.53M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $52.32M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $35.54M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $35.20M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $91.14M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $65.05M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $71.68M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $69.37M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $75.48M | Mar 6, 2020 |
| FY2018 | Dec 31, 2016 | $94.16M | Mar 6, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $337.23M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $258.69M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $134.40M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $76.60M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $72.30M | Feb 22, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($42.48M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($44.81M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($89.72M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($70.04M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | ($152.55M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | ($81.44M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | ($76.48M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | ($70.27M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | ($65.19M) | Mar 6, 2020 |
| FY2018 | Dec 31, 2016 | ($92.53M) | Mar 6, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.49M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.01M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $344.0K | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $55.0K | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.87M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $324.0K | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $325.0K | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $311.0K | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $2.36M | Mar 6, 2020 |
| FY2018 | Dec 31, 2016 | $4.87M | Mar 6, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $501.60M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $435.75M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $297.58M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $190.07M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $149.91M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $201.56M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $259.78M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $183.33M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | $157.90M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $213.13M | Mar 14, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $334.66M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $262.47M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $130.76M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $91.74M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $67.30M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $75.45M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $73.13M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $67.52M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | $18.59M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $19.98M | Mar 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $166.95M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $173.29M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $166.82M | Feb 19, 2026 |
| FY2025 | Dec 31, 2022 | $98.33M | Feb 19, 2026 |
| FY2024 | Dec 31, 2021 | $82.62M | Feb 20, 2025 |
| FY2023 | Dec 31, 2020 | $126.11M | Feb 22, 2024 |
| FY2022 | Dec 31, 2019 | $186.66M | Mar 2, 2023 |
| FY2021 | Dec 31, 2018 | $115.81M | Feb 28, 2022 |
| FY2020 | Dec 31, 2017 | $139.31M | Mar 8, 2021 |
| FY2019 | Dec 31, 2016 | $193.15M | Mar 6, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($946.94M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($885.34M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | ($846.20M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | ($780.14M) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($712.93M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($554.77M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($460.45M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($365.51M) | Mar 6, 2020 |
| FY2018 | Jan 1, 2018 | $4.00M | Mar 6, 2019 |
| FY2018 | Dec 31, 2017 | ($278.21M) | Mar 6, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $68.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $64.93M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $21.47M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $96.14M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $72.43M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $91.03M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $181.13M | Mar 8, 2021 |
| FY2020 | Dec 31, 2018 | $78.77M | Mar 8, 2021 |
| FY2020 | Dec 31, 2017 | $75.38M | Mar 8, 2021 |
| FY2019 | Dec 31, 2016 | $74.60M | Mar 6, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $202.83M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $150.85M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $49.82M | Feb 20, 2025 |
| FY2022 | Dec 31, 2022 | $26.71M | Mar 2, 2023 |
| FY2021 | Dec 31, 2021 | $32.26M | Feb 28, 2022 |
| FY2020 | Dec 31, 2020 | $50.79M | Mar 8, 2021 |
| FY2019 | Dec 31, 2019 | $50.01M | Mar 6, 2020 |
| FY2018 | Dec 31, 2018 | $51.98M | Mar 6, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 28, 2022 |
| FY2018 | Dec 31, 2017 | 0 | Mar 6, 2019 |
| FY2018 | Sep 30, 2017 | 0 | Mar 6, 2019 |
| FY2018 | Jun 30, 2017 | 0 | Mar 6, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Feb 28, 2022 |
| FY2018 | Dec 31, 2017 | 0 | Mar 6, 2019 |
| FY2018 | Sep 30, 2017 | 0 | Mar 6, 2019 |
| FY2018 | Jun 30, 2017 | 0 | Mar 6, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 244.35M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 238.02M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 232.45M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | 198.58M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | 130.18M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | 93.60M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 88.82M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | 62.52M | Mar 6, 2020 |
| FY2018 | Dec 31, 2017 | 47.53M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | 47.31M | Mar 14, 2018 |